Favipiravir (CAS No. 259793-96-9) in bulk form. Favipiravir is a pyrazinecarboxamide derivative with activity against RNA viruses. It is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Currently, Favipiravir is undergoing phase 2 clinical trials for the treatment of Covid-19 in the United States and it is also indicated for the treatment of influenza in Japan.
[1] Please importantly note that only the relevant portion of the related is displayed above. You may refer to the said customs ruling for the entire ruling explanation.
[1]. https://rulings.cbp.gov/ruling/N314505